2023
Comorbid alcohol use disorder and posttraumatic stress disorder: A proof‐of‐concept randomized placebo‐controlled trial of buprenorphine and naltrexone combination treatment
Davis L, Petrakis I, Pilkinton P, Nolen T, Vandergrift N, Hirsch S, Norrholm S, Kosten T. Comorbid alcohol use disorder and posttraumatic stress disorder: A proof‐of‐concept randomized placebo‐controlled trial of buprenorphine and naltrexone combination treatment. Alcohol Clinical And Experimental Research 2023, 47: 1756-1772. PMID: 37468230, DOI: 10.1111/acer.15155.Peer-Reviewed Original ResearchComorbid alcohol use disorderAlcohol use disorderPosttraumatic stress disorderPlacebo-controlled trialWorld Health OrganizationReceptor antagonismOpioid receptorsUse disordersExtended-release injectable naltrexoneKappa-opioid receptor antagonistStress disorderClinician-Administered PTSD ScalePrimary composite outcomeEffective pharmacologic treatmentOpioid receptor antagonistOpioid receptor antagonismMu-opioid receptorsCombination of buprenorphineBinary primary outcomeTimeline Follow-BackAUD outcomesBuprenorphine 2Injectable placeboPrimary timepointInjectable naltrexone
2008
Alcohol Detoxification and Relapse Prevention Using Valproic Acid Versus Gabapentin in Alcohol-dependent Patients
Trevisan L, Ralevski E, Keegan K, Oville A, Vuppalapati D, Gonzalez G, Limoncelli D, Petrakis I. Alcohol Detoxification and Relapse Prevention Using Valproic Acid Versus Gabapentin in Alcohol-dependent Patients. Addictive Disorders & Their Treatment 2008, 7: 119-128. DOI: 10.1097/adt.0b013e31812e6a3c.Peer-Reviewed Original ResearchAlcohol withdrawalDays of treatmentSleep disturbancesAlcohol detoxificationModerate withdrawalValproic acidAcute alcohol withdrawalPlacebo-controlled trialMild withdrawal symptomsDoses of benzodiazepinesPrevention of relapseAlcohol-dependent patientsSymptoms of depressionPhysiologic withdrawalPostwithdrawal periodSupportive treatmentAcute symptomsBenzodiazepine medicationWithdrawal symptomsAcute withdrawalPsychiatric symptomsMale veteransClinical importancePsychiatric distressRelapse prevention
1998
Naltrexone Augmentation of Neuroleptics in Schizophrenia
Sernyak M, Glazer W, Heninger G, Charney D, Woods S, Petrakis I, Krystal J, Price L. Naltrexone Augmentation of Neuroleptics in Schizophrenia. Journal Of Clinical Psychopharmacology 1998, 18: 248-251.. PMID: 9617985, DOI: 10.1097/00004714-199806000-00011.Peer-Reviewed Original ResearchConceptsBrief Psychiatric Rating ScaleTotal BPRS scoreBPRS scoresNegative symptomsAddition of naltrexoneBPRS subscale scoresOngoing neuroleptic treatmentSingle-blind basisPlacebo-controlled trialSingle-blind fashionSubscale scoresBPRS total scorePsychiatric Rating ScaleDSM-III criteriaSubsequent treatmentRepeated-measures analysisNaltrexone augmentationNeuroleptic medicinesNeuroleptic regimenTransient exacerbationPlacebo armNeuroleptic treatmentClinical benefitRepeated-measures ANOVANaltrexone